Rational Vaccines is developing live-attenuated vaccines targeting herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) using proprietary viral immunotherapeutic technology. The company aims to reduce the prevalence and transmission of herpes infections, addressing the lack of effective vaccines and treatments for this widespread viral disease.
Funding
$75.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFounders
Product
Problem
Herpes simplex virus (HSV) infections are highly prevalent, affecting billions globally and often spreading asymptomatically. Current treatments offer limited relief, and there is no effective vaccine to prevent the spread of HSV-1 and HSV-2.
Solution
Rational Vaccines is developing live-attenuated vaccines designed to combat diseases resulting from HSV-1 and HSV-2 infections. Using proprietary viral immunotherapeutic technology, the company aims to reduce the suffering of those infected and curb the transmission of the virus. These rationally engineered vaccine candidates are designed to provide both immunotherapeutic and prophylactic benefits.
Target Audience
The primary target audience includes individuals at risk of contracting herpes simplex virus, as well as those already infected seeking therapeutic options.
Features
- Live-attenuated vaccine approach to stimulate a broad and durable immune response
- Proprietary viral immunotherapeutic technology for targeted immune modulation
- Vaccine candidates designed for both therapeutic and prophylactic use against HSV-1 and HSV-2